Drugs / TAS-114
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02454062 | Mar 2013 → Dec 2016 | neoplasm | Taiho Oncology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02025803 | Nov 2012 → Jul 2017 | neoplasm | Taiho Oncology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01610479 | Jun 2012 → Feb 2017 | cancer | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02855125 Comparator | Aug 2016 → Sep 2017 | non-small cell lung carcinoma | Taiho Oncology, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02855125 ↗ |
| Action | Inhibit | “novel dUTPase inhibitor” PMID 30511200 ↗ Dec 2018 |
| Route | Oral | “TAS-114 and S-1 were concurrently administered orally under fasting conditions” PMID 30511200 ↗ Dec 2018 |